LCZ696 surpasses enalapril for heart failure
August 31, 2014|Internal Medicine News
Author and Disclosure Information
AT THE ESC CONGRESS 2014
"By switching patients from an ACE inhibitor to LCZ696 you can prolong patient survival. It is exciting to have a new drug" that can confer as many benefits as LCZ696, Dr. Jessup said.
PARADIGM-HF was sponsored by Novartis. Dr. Packer has been a consultant to Novartis as well as several other companies. Dr. Jessup had no disclosures. Dr. Cleland has received research support and honoraria from Sorin, St. Jude, and Medtronic.
Twitter: @mitchelzoler
